CD274 and urothelial carcinoma: In order to address the challenges faced by pathology laboratories, which must perform multiple PD-L1 IHC assays to screen patients who might be eligible for various ICIs, efforts are needed to harmonize the PD- L1 scoring systems for patients with urothelial carcinoma (12).